ArticleHepatology (Baltimore, Md.)2022

Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice.

Bing Xin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.